vilazodone Side Effects
Also known as: Viibryd
Analysis of 9,764 adverse event reports submitted to the FDA from 2009 to 2025.
Total Reports
9,764
Death-Related
328
3.4% of reports
Hospitalizations
1,195
12.2% of reports
Top Indication
Depression
Most Reported Adverse Reactions
Who Reports Side Effects
Gender Distribution
Age Distribution
Reporting Trend by Year
Reactions in Death Reports
Top reactions reported in 328 reports where death was an outcome. These are voluntarily reported and do not establish causation.
| Reaction | Reports |
|---|---|
| COMPLETED SUICIDE | 174 |
| DEATH | 77 |
| TOXICITY TO VARIOUS AGENTS | 38 |
| CARDIO-RESPIRATORY ARREST | 22 |
| CARDIAC ARREST | 15 |
| OVERDOSE | 15 |
| SUSPECTED SUICIDE | 13 |
| RESPIRATORY ARREST | 10 |
| OFF LABEL USE | 9 |
| ACUTE KIDNEY INJURY | 8 |
| GUN SHOT WOUND | 8 |
| INTENTIONAL OVERDOSE | 8 |
| FATIGUE | 7 |
| HYPERTHERMIA | 6 |
| HYPOTENSION | 6 |
| NAUSEA | 6 |
| PNEUMONIA | 6 |
| PULMONARY OEDEMA | 6 |
| RENAL FAILURE | 6 |
| BRADYCARDIA | 5 |
Reactions in Hospitalization Reports
Top reactions in 1,195 reports where hospitalization was an outcome.
| Reaction | Reports |
|---|---|
| NAUSEA | 90 |
| ANXIETY | 86 |
| DEPRESSION | 79 |
| SEROTONIN SYNDROME | 79 |
| SUICIDAL IDEATION | 74 |
| FALL | 73 |
| HEADACHE | 73 |
| VOMITING | 68 |
| FATIGUE | 64 |
| PAIN | 61 |
| DIARRHOEA | 60 |
| DRUG INEFFECTIVE | 60 |
| OFF LABEL USE | 58 |
| DIZZINESS | 53 |
| SUICIDE ATTEMPT | 52 |
| DYSPNOEA | 48 |
| ASTHENIA | 46 |
| OVERDOSE | 46 |
| TREMOR | 43 |
| HOSPITALISATION | 42 |
Nearby — Related Medications
What the FAERS Data Reveals About vilazodone Side Effects
The FDA Adverse Event Reporting System (FAERS) contains 9,764 voluntary reports linked to vilazodone and its brand equivalents (Viibryd), spanning 2009 through 2025. Of those, 328 (3.4%) listed death as an outcome and 1,195 (12.2%) involved hospitalization. The most common indication reported alongside adverse events was Depression.
Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 72% were female and 28% male; age distribution skews toward 45-64, with 2,351 reports in that bracket. The single most reported reaction is off label use with 1,111 submissions, followed by diarrhoea and nausea.
FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice — speak with a licensed clinician about any side-effect concerns.
Read our methodology — how this data is sourced, computed, and verified.